Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Nonalcoholic fatty liver disease (NAFLD), defined by fatty infiltration of the liver in the
absence of excess alcohol consumption, affects an estimated 30% of adults in the United
States. A proportion of people with NAFLD will develop progressive, inflammatory nonalcoholic
steatohepatitis (NASH), which can progress to liver cirrhosis and liver failure. NAFLD is
expected to be the most common indication for liver transplantation by the year 2020. We
hypothesize that among adults with NAFLD, aspirin will reduce intrahepatic lipid content, as
quantified by 1H magnetic resonance spectroscopy (1H-MRS).